All Articles
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose. Read More ›
Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib. Read More ›
Join our webinar discussion to learn about the key challenges and real-life best practices for biosimilar adoption, including how tools, processes and expert support from VitalSource (TM) GPO help practices navigate the dynamic and rapidly evolving landscape. Read More ›
Personalized starting doses of niraparib based on body weight and platelet count are associated with reductions in thrombocytopenia and other hematologic events. Read More ›
Treatment with rucaparib was associated with improvements in progression-free survival, time to first subsequent treatment, and other post-progression efficacy end points. Read More ›
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease. Read More ›
Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone. Read More ›
When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients. Read More ›
In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability. Read More ›